Sequence first: three tracks run in parallel, but parameters lock in order
Validating a sterile barrier system is not a single production line. It is three tracks moving at once: validation of the packaging forming process (can the sealing process reliably produce an acceptable seal), performance qualification of the packaging system (sterile barrier integrity and shelf life), and validation of the sterilization process (is this sterilization method suitable for this packaging, and is the packaging still effective after sterilization).
There is exactly one hard sequencing constraint: the seal process parameters have to be locked before the other two tracks mean anything. ISO 11607 treats packaging forming and sealing as processes that require validation, which means the samples sent for performance testing and for sterilization validation must carry seal parameters drawn from a validated process window — not "a few sealed by hand in the lab".
Getting this backwards has a direct price. You complete the full set of packaging performance tests and the sterilization validation, then find at production scale that the seal parameters need adjusting, and the applicability of every data set behind you is overturned. The project is back at the start.
Three points where the two validation tracks meet
| Handoff point | Upstream input | Downstream output | Consequence of getting it out of order |
|---|---|---|---|
| Packaging material compatible with the sterilization method | Material permeability and resistance data | Conclusion on the feasibility of the sterilization method | A non-permeable material chosen for a gas sterilization route writes off the whole packaging run |
| Packaging performance after sterilization | Loading configuration and worst-case location from sterilization validation | Source of the samples for aging and integrity testing | Integrity testing on unsterilized samples produces data that will not be accepted |
| Bioburden and sterility assurance | Initial contamination level of product and packaging | Basis on which the sterilization process is established | Bioburden sampling that excludes the packaging leaves the sterilization validation resting on an incomplete basis |
Of the three, packaging performance after sterilization is the one most often skipped. Many projects schedule packaging performance testing ahead of sterilization, usually because "sterilization slots are hard to book". The result is that sterilization has a real effect on the packaging — through heat and moisture, pressure change, or radiation energy — and performance data from unsterilized samples say nothing about the post-sterilization state. Any sample used to support a shelf-life or sterile barrier claim has to go through sterilization equivalent to actual production, and normally under worst-case conditions.
Can samples be shared: a reference table
| Test or validation activity | Can samples be shared with other activities? | Precondition |
|---|---|---|
| Seal process validation | Not shared with downstream activities | Must cover the boundary settings of the process window; the samples serve one purpose only |
| Sterile barrier integrity | Can be shared with the aging group | Same lot, same seal parameters, same sterilization treatment |
| Post-aging performance | Can be shared with the shelf-life file | Sampling points and acceptance criteria already locked at protocol stage |
| Sterilization process validation | Generally not shared | Requires worst-case loading; the samples have a history that differs from routine production |
| Bioburden determination | Not shared | Sampling occurs before sterilization and the samples are consumed destructively |
| Sterility testing | Not shared | Destructive, and the samples must be disposed of as specified |
Sharing samples saves money, but sharing them in the wrong place invalidates a whole data set. The test is one sentence long: do the two activities require the same sample history? If the history differs — sterilized or not, aged or not, worst-case or not — the samples cannot be shared.
Why bioburden has to come first
Determining the initial contamination level of the product using the methods of ISO 11737-1 is one of the inputs to sterilization process validation. Whether the route is ethylene oxide (ISO 11135) or irradiation (ISO 11137), establishing the sterilization process starts from bioburden data. Schedules routinely push this step to the back because it looks like "just a microbiology test"; in reality it is the head of the entire sterilization validation chain.
Two errors show up again and again in practice.
The first is bioburden sampling that covers only the product and not the packaging. The inner surfaces of a sterile barrier system carry microorganisms too, so the protocol has to state clearly what is being sampled — the device alone, or the device together with its primary packaging. Define the sampling object wrongly and everything the sterilization validation is built on is incomplete.
The second is carrying over old bioburden data. Bioburden levels drift when the manufacturing environment, raw material suppliers or batch size change. Supporting a new sterilization validation with stale data is an easy thing for an auditor to pick up. Bioburden needs routine monitoring at a defined frequency; it is not a one-off exercise that stays valid indefinitely.
Ethylene oxide and irradiation: entirely different constraints on packaging
| Sterilization method | Key constraint on the packaging | What packaging validation has to cover additionally |
|---|---|---|
| Ethylene oxide (ISO 11135) | The material must allow sterilant gas and moisture to pass in and out, and must withstand pressure change | Effect of the aeration process on the material, and seal integrity after pressure cycling |
| Irradiation (ISO 11137) | The material may discolour, embrittle or lose strength after irradiation | Change in material properties after irradiation, and long-term behaviour when irradiation is followed by aging |
The practical way to use this table is to work backwards at the material selection stage: fix the sterilization method first, then choose the packaging material. Doing it the other way round — selecting packaging on cost and appearance, then asking whether it can be sterilized — is one of the more expensive kinds of rework in a packaging project. Change the material and the sealing process has to be re-validated, the performance tests have to be repeated, and the aging clock restarts.
One further point is easy to overlook. If a single product is planned for two sterilization routes, for example different routes at different manufacturing sites, packaging validation has to cover the effects of both. You cannot validate one and then claim the other is "gentler". Whether it is gentler needs data, not inference.
Four typical rework scenarios and how to avoid them
Scenario one: seal parameters adjusted midway through validation. Early trial seals gave a disappointing pass rate, engineering changed the seal parameters, but the samples already committed to aging were not re-committed. The aging data now correspond to the old parameters. Avoidance: treat any parameter adjustment as process re-validation and re-commit the aging group at the same time. Do not gamble on it.
Scenario two: sterilization validation loading differs from production. Validation was run with a small load, production runs full, and the definition of the worst-case location changes with it, so the validation conclusion no longer covers actual manufacturing. Avoidance: define the loading configuration against the production plan before validation begins, including the basis for selecting the worst-case location and how it will be verified.
Scenario three: packaging performance testing and sterilization validation run by separate teams, each sending its own samples. The lot numbers and seal records on the two sides do not reconcile, and the pieces never assemble into one coherent file. Avoidance: keep a sample register. Every sample released is logged with lot, seal parameters, sterilization lot, destination and return status, and one person maintains the register.
Scenario four: material discolouration discovered only after irradiation. Appearance fails while device performance is fine. A small irradiation compatibility screening at the material selection stage would have surfaced this early; discovering it during formal validation costs the material batch and a full scheduling cycle.
Self-check at the handoff points
- Was the sterilization method fixed before the packaging material was finalized, rather than the reverse
- Has the sealing process completed process validation, with the parameters locked into a controlled document
- Have all samples used for performance and aging testing been sterilized equivalently to production
- Does the bioburden sampling object include the packaging, and is the sampling frequency part of the routine monitoring plan
- Do the loading configuration and worst-case definition in the sterilization validation match production
- Can the sample register trace every report back to a specific lot and set of seal parameters
- Do the reports from the two tracks cross-reference each other's numbers, closing the loop instead of standing alone
For scheduling on the packaging side see packaging validation, and for the sterilization side see sterilization validation. How accelerated and real-time aging evidence is organized is covered in a separate article; for how the projects combine, start with shelf life and aging. For the milestones from sample receipt to report issue, see our service process.
Getting the two schedules aligned
The handoff between packaging and sterilization is, at bottom, a scheduling problem: whose conclusion feeds whose, and what happens when you push ahead before the input has arrived. Push ahead and rework is close to unavoidable. Send over the packaging structure, the material list, the sterilization method you intend to use and the production loading plan, and we can map out the handoff points and sample requirements first, then come back with a test package and schedule. SUNGO Lab (Shanghai Shage Medical Technology Co., Ltd.) is a medical device testing laboratory accredited by CNAS, CMA and IAS (USA), with laboratories in Shanghai and Hefei. Please note that accreditation marks only demonstrate that the laboratory holds the relevant technical competence within its accredited scope; they do not constitute a commitment regarding market access in the target market, and the final conclusion still rests on the test data and the review requirements of that market. To discuss a project, call +86 132 4819 8029 or submit your documentation through request a quote.